Edwards Lifesciences Corporation
EW
$67.95
-$0.56-0.82%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 8.57% | 4.48% | 0.81% | -3.03% | -6.92% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8.57% | 4.48% | 0.81% | -3.03% | -6.92% |
| Cost of Revenue | 14.22% | 9.24% | 7.81% | 1.69% | -9.31% |
| Gross Profit | 7.20% | 3.34% | -0.85% | -4.15% | -6.32% |
| SG&A Expenses | 13.11% | 8.69% | 6.49% | 3.42% | 0.94% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -187.27% | -200.00% | -200.00% | -- |
| Total Operating Expenses | 12.38% | -0.83% | -2.81% | 0.88% | -1.89% |
| Operating Income | -0.45% | 18.47% | 9.73% | -11.29% | -16.99% |
| Income Before Tax | 12.80% | 4.14% | 1.74% | -16.71% | -22.35% |
| Income Tax Expenses | -0.20% | -21.26% | -19.55% | -32.68% | -37.92% |
| Earnings from Continuing Operations | 14.43% | 7.69% | 4.87% | -14.20% | -19.84% |
| Earnings from Discontinued Operations | 1,446.10% | 1,840.48% | 19.68% | 331.85% | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 63.33% | 35.71% | 125.00% | -- | -- |
| Net Income | 197.68% | 190.65% | 6.01% | -5.04% | -7.85% |
| EBIT | -0.45% | 18.47% | 9.73% | -11.29% | -16.99% |
| EBITDA | 0.22% | 17.12% | 9.47% | -9.99% | -15.49% |
| EPS Basic | 202.33% | 195.52% | 7.40% | -3.43% | -5.99% |
| Normalized Basic EPS | 4.58% | 21.99% | 12.89% | -7.20% | -12.90% |
| EPS Diluted | 203.60% | 196.64% | 7.40% | -3.15% | -5.76% |
| Normalized Diluted EPS | 4.75% | 22.25% | 13.16% | -6.93% | -12.53% |
| Average Basic Shares Outstanding | -1.48% | -1.16% | -1.28% | -1.65% | -1.98% |
| Average Diluted Shares Outstanding | -1.67% | -1.37% | -1.51% | -1.92% | -2.37% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
